Valuation: Simulations Plus, Inc.

Market Cap 371M 326M 304M 279M 522M 35.51B 535M 3.61B 1.41B 17.57B 1.39B 1.36B 60.74B P/E 2026 *
43.6x
P/E 2027 * 40.1x
Enterprise Value 371M 326M 304M 279M 522M 35.51B 535M 3.61B 1.41B 17.57B 1.39B 1.36B 60.74B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.08%
Yield 2026 *
-
Yield 2027 * -
1 week+0.44%
Current month+0.11%
1 month-0.27%
3 months+31.02%
6 months+3.50%
Current year+0.55%
1 week 18.3
Extreme 18.3002
18.39
1 month 18.19
Extreme 18.19
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.9
Extreme 7.9
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

Executive/Senior Manager

-1,000 0.0050%
01/07/26 Sell

Founder

-4,177 0.0207%
16/06/26 Fiscal year

Executive/Senior Manager

22,050 0.1094%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.44%+36.08%-62.85% 371M
+3.33%+12.66%-27.62%+3.21% 33.77B
-1.98%-0.88%-49.75%+133.61% 11.86B
+1.51%+4.12%-23.25%+67.57% 5.61B
-2.15%+3.34% - - 2.16B
-3.83%+1.32%+39.79%-34.24% 1.88B
-0.46%-5.90% - - 1.68B
-1.29%-5.23%-36.88% - 1.02B
-2.72%-0.92%+30.00%+97.70% 847M
+0.89%+3.99%-41.95%-54.07% 776M
Average -0.67%+0.86%-9.20%+21.56% 6B
Weighted average by Cap. +1.37%+6.39%-28.67%+36.74%

Financials

2026 *2027 *
Net sales 81.87M 71.94M 67.15M 61.63M 115M 7.84B 118M 796M 311M 3.88B 307M 301M 13.42B 86.26M 75.8M 70.75M 64.93M 122M 8.26B 125M 839M 328M 4.09B 324M 317M 14.13B
Net income 9.53M 8.38M 7.82M 7.18M 13.43M 913M 13.76M 92.72M 36.26M 452M 35.79M 35.02M 1.56B 10.18M 8.95M 8.35M 7.66M 14.35M 975M 14.7M 99.02M 38.73M 483M 38.23M 37.4M 1.67B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
29/07/26 $18.33 0.00% 346,154
28/07/26 $18.33 0.00% 158,846
27/07/26 $18.33 -0.05% 391,624
24/07/26 $18.34 +0.05% 240,703
23/07/26 $18.33 +0.44% 571,006
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.33USD
Average target price
17.25USD
Spread / Average Target
-5.89%

Quarterly revenue - Rate of surprise